Ayalandi - Kiingereza - HPRA (Health Products Regulatory Authority)

pfizer limited - fluconazole - powder for oral suspension - 40 mg/ml - triazole derivatives

Ayalandi - Kiingereza - HPRA (Health Products Regulatory Authority)

pfizer limited - fluconazole - powder for oral suspension - 10 mg/ml - triazole derivatives

Ubelgiji - Kiingereza - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

pfizer sa-nv - fluconazole 200 mg/100 ml - solution for infusion - fluconazole

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - fluconazole, quantity: 100 mg - capsule, hard - excipient ingredients: patent blue v; colloidal anhydrous silica; titanium dioxide; sodium lauryl sulfate; magnesium stearate; gelatin; lactose monohydrate; maize starch; erythrosine; butan-1-ol; shellac; industrial methylated spirit; dimeticone 1510; iron oxide black; lecithin; propylene glycol; isopropyl alcohol; purified water; ethanol; strong ammonia solution; potassium hydroxide - indications as at 21 june 2005 : diflucan, given orally, is indicated for: 1. treatment of cryptococcal meningitis in patients who are unable to tolerate amphotericin b. note : data suggest that the clinical efficacy of diflucan is lower than that of amphotericin b in the treatment of the acute phase of cryptococcal meningitis. 2. maintenance therapy to prevent relapse of cryptococcal meningitis in patients with aids. 3. treatment of oropharyngeal and oesophageal candidiasis in aids and other immunosuppressed patients. 4. secondary prophylaxis of oropharyngeal candidiasis in patients with hiv infection. 5. serious and life-threatening candida infections in patients who are unable to tolerate amphotericin b. note : it remains to be shown that diflucan is as effective as amphotericin b in the treatment of serious and life-threatening candida infections. until such data are available, amphotericin b remains the drug of choice. 6. vaginal candidiasis when topical therapy has failed. 7. treatment of exten

Ayalandi - Kiingereza - HPRA (Health Products Regulatory Authority)

pfizer healthcare ireland - fluconazole - powder for oral suspension - 10 milligram(s)/millilitre - triazole derivatives; fluconazole

Ayalandi - Kiingereza - HPRA (Health Products Regulatory Authority)

pfizer healthcare ireland - fluconazole - powder for oral suspension - 40 milligram(s)/millilitre - triazole derivatives; fluconazole

Panama - Kiingereza - Ministerio de Salud (Dirección Nacional de Farmacia Y Drogas)

pfizer holding france - fluconazol - fluconazol....2.0 mg

Kanada - Kiingereza - Health Canada

pfizer canada ulc - fluconazole - solution - 2mg - fluconazole 2mg - azoles

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - fluconazole, quantity: 50 mg - capsule, hard - excipient ingredients: patent blue v; colloidal anhydrous silica; titanium dioxide; sodium lauryl sulfate; gelatin; magnesium stearate; lactose monohydrate; maize starch; butan-1-ol; shellac; industrial methylated spirit; dimeticone 1510; iron oxide black; lecithin; propylene glycol; isopropyl alcohol; purified water; ethanol; strong ammonia solution; potassium hydroxide - indications as at 21 june 2005 : diflucan, given orally, is indicated for: 1. treatment of cryptococcal meningitis in patients who are unable to tolerate amphotericin b. note : data suggest that the clinical efficacy of diflucan is lower than that of amphotericin b in the treatment of the acute phase of cryptococcal meningitis. 2. maintenance therapy to prevent relapse of cryptococcal meningitis in patients with aids. 3. treatment of oropharyngeal and oesophageal candidiasis in aids and other immunosuppressed patients. 4. secondary prophylaxis of oropharyngeal candidiasis in patients with hiv infection. 5. serious and life-threatening candida infections in patients who are unable to tolerate amphotericin b. note : it remains to be shown that diflucan is as effective as amphotericin b in the treatment of serious and life-threatening candida infections. until such data are available, amphotericin b remains the drug of choice. 6. vaginal candidiasis when topical therapy has failed. 7. treatment of exten